Invasive measures and clinical implications
| Measure | Abnormality | Clinical implications |
|---|---|---|
| mPAP (mm Hg) | mPAP ≥25mmHg | Definition of group 1–5 (2013 World Symposium on Pulmonary Hypertension (WSPH) classification) |
| mPAP/mSAP | mPAP/mSAP >0.3 mPAP/mSAP >0.75 | Adjunct criterion for definition of group 1–5 Higher mortality |
| PCWP (mm Hg) | PCWP >15 mm Hg | Postcapillary PH, group 2 |
| Mean RAP | Mean RAP >15 mm Hg Mean RAP >20 mm Hg | RV failure, higher mortality Contraindication for balloon atrioseptostomy |
| PVRI, Wood units×m2 | PVRI >3 WU×m2 PVRI >8 WU×m2 PVRI >15 WU×m2 | Group 1–5 Inoperability in APAH-CHD Higher mortality |
| Fick or thermodilution CI, L/min×m2 | CI <2.5 L/min×m2 | Low cardiac output, higher mortality |
| SVO2, % | SVO2 <55% | Low cardiac output, higher mortality |
APAH-CHD, pulmonary arterial hypertension associated with congenital heart disease; CI, cardiac index; mPAP, mean pulmonary arterial pressure; mSAP, mean systemic arterial pressure; PCWP, pulmonary capillary wedge pressure; PH, pulmonary hypertension; PVRI, Pulmonary vascular resistance index; RAP, right atrial pressure.